Cathie Wood's weekly recap: adds AMD, CRSP; cuts PINS, PD, TER
Seeking Alpha News (Mon, 23-Feb 7:46 AM ET)
Twist Bioscience to Present at Upcoming Investor Conferences
Business Wire (Wed, 18-Feb 8:00 AM ET)
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
Business Wire (Tue, 17-Feb 7:00 AM ET)
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
Business Wire (Tue, 10-Feb 8:00 AM ET)
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Tue, 3-Feb 8:00 AM ET)
Twist Bioscience Delivers Fiscal Q1 2026 Results—Innovative Platform Drives Growth Focus
Market Chameleon (Mon, 2-Feb 2:52 AM ET)
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results
Business Wire (Mon, 2-Feb 7:15 AM ET)
Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue
Business Wire (Mon, 12-Jan 8:00 AM ET)
Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference
Business Wire (Thu, 18-Dec 8:00 AM ET)
Business Wire (Fri, 12-Dec 1:15 PM ET)
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Twist Bioscience trades on the NASDAQ stock market under the symbol TWST.
As of February 27, 2026, TWST stock price declined to $46.73 with 109,871 million shares trading.
TWST has a beta of 1.25, meaning it tends to be more sensitive to market movements. TWST has a correlation of 0.10 to the broad based SPY ETF.
TWST has a market cap of $2.86 billion. This is considered a Mid Cap stock.
Last quarter Twist Bioscience reported $104 million in Revenue and -$.50 earnings per share. This beat revenue expectation by $974,498 and met earnings estimates .
In the last 3 years, TWST traded as high as $60.90 and as low as $11.46.
The top ETF exchange traded funds that TWST belongs to (by Net Assets): ARKK, ARKG, XBI, VTI, IWM.
TWST has underperformed the market in the last year with a price return of +13.1% while the SPY ETF gained +16.4%. However, in the short term, TWST had mixed performance relative to the market. It has outperformed in the last 3 months, returning +47.4% vs +1.0% return in SPY. But in the last 2 weeks, TWST shares have been beat by the market, returning -2.0% compared to an SPY return of +0.5%.
TWST support price is $46.79 and resistance is $50.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TWST shares will trade within this expected range on the day.